Press Releases Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.62 ^USD	+3.12%		-9.59%	+9.48%

Apr. 25	Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer	RE
Apr. 22	Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals	Apr. 25	AQ
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ ANDA Litigation	Apr. 23	AQ
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation	Apr. 22	PR
Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan	Apr. 17	PR
Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak	Apr. 17	PR
VANDA Pharmaceuticals States A Fifth Amendment Claim Against The Government For Taking A Trade Secret	Apr. 03	AQ
Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder	Apr. 02	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA	Mar. 27	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA	Mar. 19	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA	Mar. 11	PR
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia	Mar. 06	PR
Does Government Disclosure Of A Company's Trade Secrets Amount To An Unlawful Taking Under The Fifth Amendment?	Feb. 21	AQ
Vanda: Q4 Earnings Snapshot	Feb. 07	AQ
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results	Feb. 07	PR
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia	Feb. 05	PR
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024	Jan. 31	PR
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis	Jan. 31	PR
Court Orders FDA to Resolve Vanda Pharmaceuticals Jet Lag Hearing Request by March 5, 2024	Jan. 31	AQ
Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024	Jan. 30	PR
Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024	Jan. 29	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Press Releases

Filters